Narrative ReviewTreatment: PharmacologicalComorbidities & Related ConditionsPain Science & Central SensitizationClinical RelevanceDOI
3 min read
Jump to:

Patient-friendly summary

If you read nothing else

For fibromyalgia pain, the medicines with the strongest research support are pregabalin, duloxetine, and milnacipran, while treating its mood and thinking symptoms still needs more research.

Bottom line

Pregabalin, duloxetine, and milnacipran are the pharmacological treatments best supported by evidence for fibromyalgia pain, but the mood and cognitive aspects remain under-researched.

Moderate evidence

Published

2021
5 years ago
Recent

Evidence hierarchy

Meta-analysis
Systematic Review
RCT
Cohort
Case-Control
Case Report ◀ this study
Expert Opinion

Study participants

Not reported

Patients with fibromyalgia studied in the reviewed pharmacological literature

Full research — for clinicians and curious readers

Study Summary

This conference-abstract literature review examined the level of evidence supporting pharmacological treatment of fibromyalgia, a chronic condition with high psychiatric comorbidity and incompletely understood pathogenesis. Searching the main medical databases for papers published between January 2000 and August 2020, the author found that interest in fibromyalgia treatment has grown over the last decade, with the number of clinical trials nearly doubling versus the previous decade. Pregabalin, duloxetine, and milnacipran emerged as the agents best supported by evidence, particularly for the pain component, while amitriptyline, gabapentin, cyclobenzaprine, and tramadol have been studied but with weaker supporting evidence. The cognitive, sleep, and mood dimensions of fibromyalgia remain far less investigated, so no clear medication recommendation could be made for those domains.

40/100
Evidence StrengthModerate
Study Quality
Sample Size
Replication

Key Findings

Pregabalin, duloxetine, and milnacipran are best supported by evidenceHigh

The review identifies pregabalin (a gabapentinoid), duloxetine, and milnacipran (serotonin-norepinephrine reuptake inhibitors) as the pharmacological treatments most supported by evidence for fibromyalgia, especially for the pain component.

Other agents have weaker supporting evidenceMedium

Amitriptyline, gabapentin, cyclobenzaprine, and tramadol have also been studied in various clinical trials, but there is less evidence to support their use.

Non-pain dimensions are under-investigatedMedium

Cognitive dysfunction, sleep disorders, and mood disturbances have received far less investigation in clinical trials, so no clear recommendation can be made about the superiority of one agent over another for these domains.

Growing research interest in fibromyalgia treatmentLow

Interest in treating fibromyalgia has increased over the last decade, with the number of clinical trials for this indication almost doubling compared with the previous decade.

Study Methodology
Study Design
Narrative literature review (conference E-poster abstract)
Sample Size
Not reported (number of included papers not stated)
Duration
Papers published between January 2000 and August 2020 were included
Population
Studies of pharmacological treatment in patients with fibromyalgia
Outcome Measures
Level of evidence supporting pharmacological treatments · Pain component response · Cognitive, sleep, and mood outcomes

Strengths

  • Covers a broad 20-year window (2000-2020) across the main medical databases
  • Distinguishes between drugs with stronger versus weaker evidence
  • Explicitly highlights the under-researched mood, sleep, and cognitive dimensions of fibromyalgia

Limitations

  • Published only as a brief conference abstract (E-poster), so methods and full results are not detailed
  • Number of included studies and formal selection/quality-appraisal criteria are not reported
  • Narrative review by a single author, with no quantitative synthesis or effect sizes provided
  • Search paradigm focused on antidepressants, mood stabilizers, and anxiolytics, which may not capture all relevant pharmacological classes

Key Takeaways for Patients

What This Means for You

  1. 01For fibromyalgia pain, the medications with the strongest research support are pregabalin, duloxetine, and milnacipran.
  2. 02Other medicines such as amitriptyline, gabapentin, cyclobenzaprine, and tramadol have been studied but have weaker evidence behind them.
  3. 03There is currently far less research on which medications best help the cognitive ('fibro fog'), sleep, and mood problems that often come with fibromyalgia.
  4. 04Fibromyalgia often occurs alongside psychiatric conditions, so treatment usually needs to address more than pain alone — discuss the full picture with your doctor.

Read the Full Paper

Access the complete peer-reviewed study from European Psychiatry

View Full Study

Related Research

●●●●● LandmarkMeta-analysis

Efficacy of cognitive behavioral therapy for musculoskeletal pain: a systematic review and meta-analysis

Xianjun Liu et al.·Frontiers in Psychology·2026

A meta-analysis of 14 RCTs found that CBT-based interventions produce small-to-moderate reductions in pain intensity and the largest, most consistent reductions in pain catastrophizing for chronic musculoskeletal pain.

Central SensitizationRead →
●●●●● LandmarkMeta-analysis

Effectiveness of Pain Neuroscience Education in Reducing Pain, Disability, Kinesiophobia, and Catastrophizing in Patients with Chronic Low Back Pain: A Systematic Review and Meta-Analysis

Luisa Medina-Viedma et al.·Medical Sciences (Basel)·2025

A meta-analysis of 15 RCTs (810 patients) found that pain neuroscience education, usually added to exercise or physiotherapy, may reduce pain, disability, kinesiophobia, and catastrophizing in chronic low back pain, though the authors urge caution given small trials and heterogeneity.

Central SensitizationRead →
●●●●● LandmarkSystematic Review

Pain science education and exercise interventions for people with knee or hip osteoarthritis: a systematic review, content and meta-analysis

Anna Louise Hurley-Wallace et al.·BMC Musculoskeletal Disorders·2025

A systematic review and component network meta-analysis finding that pain science education had little-to-no effect on pain or function in knee/hip osteoarthritis but improved catastrophizing, kinesiophobia, and self-efficacy, especially when paired with exercise.

Central SensitizationRead →
●●●●● LandmarkNarrative Review

Pharmacologic treatment of fibromyalgia: an update

Yang Li et al.·Frontiers in Pharmacology·2025

A 2025 narrative review concluding that current fibromyalgia drugs help only a minority of patients and should be used as part of an individualized, multimodal plan alongside exercise, education, and psychological support.

PharmacologicalRead →